{
    "Question": "SquareMind CES 2024 product highlight and specification",
    "Summary": "SquareMind\n\nProduct: Swan\n\n- A disruptive software technology for skin cancer detection\n- Aims to make skin screening more accessible through digitization and leveraging AI\n- Intends to free up significant medical time and provide physicians with more data\n- Supported by Calm/Storm Ventures, Entrepreneur First, id4 ventures, EIC Accelerator innovation programme, Bpifrance, and business angels\n- Envisions a future of non-invasive healthcare and autonomous robots revolutionizing healthcare systems\n- Not commercially available yet, but set to be revealed in 2024\n- Global vision with current activities in Europe and the US",
    "Summary_cn": "SquareMind\n\n产品：Swan\n\n- 一种颠覆性的皮肤癌检测软件技术\n- 旨在通过数字化和AI的利用，使皮肤检查更易于获取\n- 意在节省大量医疗时间并为医生提供更多数据\n- 得到Calm/Storm Ventures，Entrepreneur First，id4 ventures，EIC Accelerator创新计划，Bpifrance和商业天使的支持\n- 展望未来的无侵入性医疗和自主机器人改变医疗系统\n- 尚未商业化，但计划在2024年推出\n- 全球愿景，目前在欧洲和美国进行活动"
}